These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10624549)

  • 21. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2002; 112(4):851-9. PubMed ID: 12088744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats.
    Fachinetto R; Villarinho JG; Wagner C; Pereira RP; Puntel RL; Paixão MW; Braga AL; Calixto JB; Rocha JB; Ferreira J
    Psychopharmacology (Berl); 2007 Oct; 194(3):423-32. PubMed ID: 17641876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucuna pruriens attenuates haloperidol-induced orofacial dyskinesia in rats.
    Pathan AA; Mohan M; Kasture AS; Kasture SB
    Nat Prod Res; 2011 Apr; 25(8):764-71. PubMed ID: 20635303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia.
    Sadan O; Bahat-Stromza M; Gilgun-Sherki Y; Atlas D; Melamed E; Offen D
    Clin Neuropharmacol; 2005; 28(6):285-8. PubMed ID: 16340385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective effect of Rubia cordifolia on reserpine-induced orofacial dyskinesia.
    Patil RA; Kasture SB
    Nat Prod Res; 2012; 26(22):2159-61. PubMed ID: 22092272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia.
    Naidu PS; Singh A; Kulkarni SK
    Neuropharmacology; 2003 Jun; 44(8):1100-6. PubMed ID: 12763102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Emblica officinalis tannoids on a rat model of tardive dyskinesia.
    Bhattachary SK; Bhattacharya D; Muruganandam AV
    Indian J Exp Biol; 2000 Sep; 38(9):945-7. PubMed ID: 12561957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide.
    Burger M; Fachinetto R; Calegari L; Paixão MW; Braga AL; Rocha JB
    Brain Res Bull; 2004 Dec; 64(4):339-45. PubMed ID: 15561469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs.
    Takeuchi H; Ishigooka J; Kobayashi K; Watanabe S; Miura S
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 May; 22(4):679-91. PubMed ID: 9682280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
    Goff DC; Renshaw PF; Sarid-Segal O; Dreyfuss DA; Amico ET; Ciraulo DA
    Biol Psychiatry; 1993 May; 33(10):700-6. PubMed ID: 8102552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.
    Elkashef AM; Wyatt RJ
    Schizophr Bull; 1999; 25(4):731-40. PubMed ID: 10667743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harpagophytum Procumbens Ethyl Acetate Fraction Reduces Fluphenazine-Induced Vacuous Chewing Movements and Oxidative Stress in Rat Brain.
    Schaffer LF; de Freitas CM; Chiapinotto Ceretta AP; Peroza LR; de Moraes Reis E; Krum BN; Busanello A; Boligon AA; Sudati JH; Fachinetto R; Wagner C
    Neurochem Res; 2016 May; 41(5):1170-84. PubMed ID: 26732278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation.
    Datta S; Jamwal S; Deshmukh R; Kumar P
    Eur J Pharmacol; 2016 Jan; 771():229-35. PubMed ID: 26712377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine.
    Busanello A; Leal CQ; Peroza LR; Röpke J; de Moraes Reis E; de Freitas CM; Libardoni M; de Vargas Barbosa NB; Fachinetto R
    Neurochem Res; 2017 Nov; 42(11):3033-3040. PubMed ID: 28744755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine.
    Busanello A; Peroza LR; Wagner C; Sudati JH; Pereira RP; Prestes Ade S; Rocha JB; Fachinetto R; Barbosa NB
    Pharmacol Biochem Behav; 2012 Apr; 101(2):307-10. PubMed ID: 22266770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.
    Waddington JL; Cross AJ; Gamble SJ; Bourne RC
    Science; 1983 Apr; 220(4596):530-2. PubMed ID: 6132447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation.
    An HM; Tan YL; Shi J; Wang Z; Lv MH; Soares JC; Zhou D; Yang F; Zhang XY
    Phytomedicine; 2016 Dec; 23(13):1653-1660. PubMed ID: 27823630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tardive dyskinesia in outpatients on depot phenothiazine.
    Neehall J
    West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia.
    Lister J; Andreazza AC; Navaid B; Wilson VS; Teo C; Nesarajah Y; Wilson AA; Nobrega JN; Fletcher PJ; Remington G
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():23-29. PubMed ID: 27565433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.